Literature DB >> 9395170

Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart.

S Sicouri1, S Moro, S Litovsky, M V Elizari, C Antzelevitch.   

Abstract

INTRODUCTION: Amiodarone is a potent antiarrhythmic agent used in the management of both atrial and ventricular arrhythmias. In addition to its beta-blocking properties, amiodarone is known to block the sodium, potassium, and calcium channels in the heart. Its complex electropharmacology notwithstanding, the reasons for the high efficacy of the drug remain unclear. Also not well understood is the basis for the low incidence of proarrhythmia seen with amiodarone relative to other agents with Class III actions. The present study was designed to examine the effects of chronic amiodarone in epicardial, endocardial, and M cells of the canine left ventricle. METHODS AND
RESULTS: We used standard microelectrode techniques to record transmembrane activity from endocardial, epicardial, mid-myocardial, and transmural strips isolated from the canine left ventricle. Tissues were obtained from mongrel dogs receiving amiodarone orally (30 to 40 mg/kg per day) for 30 to 45 days or from untreated controls. Chronic amiodarone produced a greater prolongation of action potential duration in epicardium and endocardium, but less of an increase, or even a decrease at slow rates, in the M region, thereby reducing transmural dispersion of repolarization. In addition, chronic amiodarone therapy suppressed the ability of the IKr blocker, d-sotalol, to induce a marked dispersion of repolarization or early afterdepolarization activity.
CONCLUSION: Our data demonstrate for the first time a direct effect of chronic amiodarone treatment to differentially alter the cellular electrophysiology of ventricular myocardium so as to produce an important decrease in transmural dispersion of repolarization, especially under conditions in which dispersion is exaggerated. These results may contribute to our understanding of the effectiveness of amiodarone in the treatment of life-threatening arrhythmias as well as to our understanding of the low incidence of proarrhythmia attending therapy with chronic amiodarone in comparison with other Class III agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395170     DOI: 10.1111/j.1540-8167.1997.tb01018.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  34 in total

1.  Effects of the gap junction uncoupler palmitoleic acid on the activation and repolarization wavefronts in isolated rabbit hearts.

Authors:  S Dhein; K Krüsemann; T Schaefer
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 2.  Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm.

Authors:  Uma Srivatsa; Nitin Wadhani; Bramah N Singh
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  Ionic mechanisms for electrical heterogeneity between rabbit Purkinje fiber and ventricular cells.

Authors:  Oleg V Aslanidi; Rakan N Sleiman; Mark R Boyett; Jules C Hancox; Henggui Zhang
Journal:  Biophys J       Date:  2010-06-02       Impact factor: 4.033

4.  The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs.

Authors:  Tanveer A Bhuiyan; Claus Graff; Jørgen K Kanters; Jimmi Nielsen; Jacob Melgaard; Jørgen Matz; Egon Toft; Johannes J Struijk
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 5.  Drug-induced spatial dispersion of repolarization.

Authors:  Charles Antzelevitch
Journal:  Cardiol J       Date:  2008       Impact factor: 2.737

Review 6.  Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.

Authors:  Charles Antzelevitch
Journal:  Europace       Date:  2007-09       Impact factor: 5.214

Review 7.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

Review 8.  A benefit-risk assessment of class III antiarrhythmic agents.

Authors:  Bente Brendorp; Oledyg Pedersen; Christian Torp-Pedersen; Naji Sahebzadah; Lars Køber
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Luiz Belardinelli; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

10.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.